Journal History

2013	The inaugural issue was released. Biomedicines was published as a quarterly journal.
2015	Biomedicines established the following section: Tumor Immunology and Immunotherapy. - Tumor Immunology and Immunotherapy was renamed as Immunology and Immunotherapy.
2016	Biomedicines was indexed in Emerging Sources Citation Index (ESCI) of the Web of Science. Biomedicines established the following section: Neurologic Disease. - Neurologic Disease was renamed as Neurobiology and Neurologic Disease.
2017	Biomedicines was indexed in Scopus (Elsevier), starting with Volume 1 (Issue 1). Biomedicines was indexed in PubMed—National Library of Medicine (NLM), starting with Volume 1 (Issue 1). Biomedicines was indexed in PubMed Central (PMC)—National Library of Medicine (NLM), starting with Volume 1 (Issue 1). Biomedicines starts the Travel Awards project.
2018	Biomedicines established the following section: Natural compounds in Biomedicine. - Natural compounds was renamed as Drug Discovery and Development.
2019	Biomedicines was indexed in Science Citation Index Expanded (SCIE)—Web of Science (Clarivate Analytics), starting with Volume 5 (Issue 1). Biomedicines established the following sections: Cancer Therapeutics; Nanotechnology and Biotechnology; Therapeutic Strategies in Different Diseases; Gene and Cell Therapy; Thrombosis and Hemostasis; Model Systems in Research and Development; Virology, Vaccines and Viral Vectors; Tumor Cell Biology. - Cancer Therapeutics was renamed as Cancer Biology and Therapeutics; - Nanotechnology and Biotechnology was renamed as Biomedical Materials and Nanomedicine; - Therapeutic Strategies in Different Diseases was renamed as Molecular and Translational Medicine; - Thrombosis and Hemostasis was discontinued; - Model Systems in Research and Development was discontinued; - Virology, Vaccines and Viral Vectors was discontinued; - Tumor Cell Biology was discontinued.
2020	Biomedicines adopted a monthly publication schedule. Biomedicines received its first Impact Factor (4.717), ranked 36/270 (Q1) in “Pharmacology & Pharmacy”, and ranked 30/138 (Q1) in “Medicine, Research & Experimental”. Biomedicines published its 1,000th paper. Biomedicines rearranges the following sections: Immunology and Immunotherapy; Neurobiology and Neurologic Disease; Drug Discovery and Development; Cancer Biology and Therapeutics; Gene and Cell Therapy; Molecular and Translational Medicine; Biomedical Materials and Nanomedicine.
2021	Biomedicines starts the Young Investigator Award project. Biomedicines organized the 1st International Electronic Conference on Biomedicine (ECB 2021). Biomedicines organized the First Canadian Peptide and Protein Community Virtual Symposium (CPPC 2021). Biomedicines received its 2020 Impact Factor (6.081), ranked 32/275 (Q1) in “Pharmacology & Pharmacy”, ranked 32/140 (Q1) in “Medicine, Research & Experimental”, and ranked 65/298 (Q1) in “Biochemistry & Molecular Biology”. Biomedicines rearranges the following sections: Molecular and Translational Medicine; Cell Biology and Pathology; Cancer Biology and Therapeutics; Immunology and Immunotherapy; Neurobiology and Neurologic Disease; Drug Discovery; Endocrinology and Metabolism Research; Gene and Cell Therapy; Biomedical Engineering in Human Health; Biomedical Materials; Molecular Genetics and Genetic Diseases; Microbiology in Human Health and Disease; Nanomedicine and Nanobiology; Drug Metabolism; Drug Delivery; Pharmacogenomic and Personalized Medicines. - Drug Delivery, Drug Metabolism and Pharmacogenomic and Personalized Medicines were merged with Drug Discovery to create a new section Drug Discovery, Development and Delivery; - Biomedical Materials was merged with Biomedical Engineering in Human Health to create a new section Biomedical Engineering and Materials; - Cancer Biology and Therapeutics was renamed as Cancer Biology and Oncology; - Neurobiology and Neurologic Disease was renamed as Neurobiology and Clinical Neuroscience.
2022	Biomedicines announced the 2022 Early-Career Women Award/2022 Young Investigator Award. Biomedicines received its 2021 Impact Factor (4.757), ranked 87/279 (Q2) in “Pharmacology & Pharmacy”, ranked 62/139 (Q2) in “Medicine, Research & Experimental”, and ranked 121/297 (Q2) in “Biochemistry & Molecular Biology”.
2023	The year 2023 marked the 10th Anniversary of Biomedicines. Biomedicines received its 2022 Impact Factor (4.7), ranked 69/277 (Q1) in “Pharmacology & Pharmacy”, ranked 54/136 (Q2) in “Medicine, Research & Experimental”, and ranked 92/285 (Q2) in “Biochemistry & Molecular Biology”. Biomedicines announced the 2024 Travel Award/2022 Best Paper Award/2023 Outstanding Reviewer Award/2023 Young Investigator Award.
2024	Biomedicines rearranges the following sections:  Neurobiology and Clinical Neuroscience; Biomedical Engineering and Materials; Nanomedicine and Nanobiology; Molecular and Translational Medicine; Cell Biology and Pathology; Endocrinology and Metabolism Research; Microbiology in Human Health and Disease; Cancer Biology and Oncology; Gene and Cell Therapy; Molecular Genetics and Genetic Diseases; Immunology and Immunotherapy; Drug Discovery, Development and Delivery. Biomedicines received its 2023 Impact Factor (3.9), ranked 85/354 (Q1) in “Pharmacology & Pharmacy”, ranked 65/189 (Q2) in “Medicine, Research & Experimental”, and ranked 106/313 (Q2) in “Biochemistry & Molecular Biology”.
2025	Biomedicine received its CiteScore (2024) of 6.8, ranked 69/433 (Q1) in “Medicine (miscellaneous)”, and ranked 49/225 (Q1) in “General Biochemistry, Genetics and Molecular Biology”. Biomedicines received its 2024 Impact Factor (3.9), ranked 88/352 (Q1) in “Pharmacology & Pharmacy”, ranked 65/195 (Q2) in “Medicine, Research & Experimental”, and ranked 114/319 (Q2) in “Biochemistry & Molecular Biology”.